Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the myelin sheath — the protective covering of nerve fibers in the brain and spinal cord — causing inflammation, demyelination, and eventually irreversible nerve fiber damage. It is the most common disabling neurological disease in young adults, typically diagnosed between ages 20 and 40, and affects approximately 1 million people in the United States.
MRI is the single most important tool in the diagnosis and ongoing management of MS — it is required for applying the McDonald diagnostic criteria and is used to monitor disease activity and treatment response over time. The white matter lesions of MS are closely related to other conditions producing white matter signal abnormalities on MRI, and accurate pattern recognition by an experienced radiologist is essential for correct diagnosis. MS-related brain atrophy is now recognized as a key outcome measure, and spinal cord involvement is an important diagnostic feature evaluated alongside brain imaging.
Causes
Immune-mediated demyelination
MS is caused by an abnormal autoimmune response in which autoreactive T-cells and B-cells breach the blood-brain barrier and attack myelin as if it were a foreign pathogen. This inflammatory cascade strips the myelin sheath from axons, slowing or blocking nerve signal transmission and producing neurological symptoms. Repeated inflammatory attacks eventually cause axonal transection — permanent nerve fiber damage — which underlies progressive disability accumulation independent of relapses.
Risk factors
MS shows strong geographic and demographic patterns that implicate both genetic and environmental factors. It is 2–3 times more common in women than men. Prevalence increases with distance from the equator — suggesting a role for vitamin D deficiency and reduced ultraviolet light exposure. Epstein-Barr virus (EBV) infection has been identified as the strongest environmental risk factor, with recent evidence suggesting molecular mimicry between EBV proteins and myelin antigens. Genetic susceptibility is significant, with HLA-DRB1 the most strongly associated gene, and a 20–40% concordance rate in identical twins confirming that genetic predisposition alone is insufficient to cause the disease.
Symptoms
MS symptoms are highly variable depending on the location and burden of demyelinating lesions. Common presentations include:
- Fatigue: The most common and often most disabling symptom — an overwhelming exhaustion disproportionate to activity that is not relieved by rest.
- Optic neuritis: Pain with eye movement followed by blurred or lost vision in one eye — a classic first presentation of MS, occurring in approximately 25% of patients at onset.
- Sensory symptoms: Numbness, tingling, or burning in the limbs or face — reflecting spinal cord or brainstem lesions.
- Lhermitte's sign: A brief electric shock sensation radiating down the spine and into the limbs with neck flexion — highly characteristic of cervical spinal cord demyelination.
- Weakness and spasticity: Limb weakness and muscle stiffness from corticospinal tract lesions.
- Balance and coordination difficulties: Gait ataxia and tremor from cerebellar lesions.
- Bladder dysfunction: Urgency, frequency, and incontinence from spinal cord involvement — affects the majority of patients over the disease course.
- Cognitive difficulties: Processing speed, attention, and memory — the cognitive profile of MS differs from Alzheimer's disease in sparing language and general knowledge until later stages.
- Double vision (diplopia): From brainstem or internuclear ophthalmoplegia — a highly specific finding for MS when present in a young patient.
Diagnosis
Diagnosis is based on the McDonald criteria, which requires demonstration of CNS lesions disseminated in space (in at least two of four characteristic locations: periventricular, juxtacortical, infratentorial, and spinal cord) and disseminated in time (lesions occurring at different time points, evidenced by new lesions on follow-up MRI or simultaneous presence of enhancing and non-enhancing lesions).
MRI of the brain and spinal cord with gadolinium contrast is the cornerstone of MS diagnosis and monitoring. The characteristic MS lesion locations — periventricular (particularly the "Dawson's fingers" pattern perpendicular to the ventricles), juxtacortical, corpus callosum, infratentorial, and spinal cord — must be distinguished from the vascular pattern of white matter lesions, which spares these regions. Gadolinium-enhancing lesions indicate active inflammation from blood-brain barrier disruption and represent recent disease activity. Serial MRI monitoring — typically annually or after treatment changes — tracks new lesion formation and brain volume loss as objective measures of disease control.
Cerebrospinal fluid analysis demonstrating oligoclonal bands (present in over 90% of MS patients) and elevated IgG index supports the diagnosis when MRI findings are insufficient. Visual evoked potentials document subclinical optic nerve demyelination. Serum anti-aquaporin-4 (AQP4) and anti-MOG antibodies are tested to exclude neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody-associated disease, which can mimic MS but require entirely different treatments.
Disease Course Classification
MS is classified by clinical course, which guides treatment intensity and strategy:
- Relapsing-Remitting MS (RRMS): The most common form, affecting approximately 85% of patients at diagnosis — distinct neurological attacks (relapses) followed by periods of partial or complete recovery. Most DMTs are designed for this form.
- Secondary Progressive MS (SPMS): Develops in many RRMS patients after years — transition to gradual, continuous worsening with or without superimposed relapses. Fewer effective treatments available.
- Primary Progressive MS (PPMS): Steady neurological decline from disease onset without distinct relapses — affects approximately 15% of patients, tends to affect older patients, and disproportionately affects the spinal cord. Ocrelizumab is the primary approved therapy.
- Clinically Isolated Syndrome (CIS): A first demyelinating episode that may or may not evolve into definite MS — MRI findings at the time of CIS are the strongest predictor of conversion to MS, making early imaging critical.
Treatments
While there is no cure for MS, disease-modifying therapies (DMTs) significantly reduce relapse frequency, slow disability accumulation, and reduce new MRI lesion formation — particularly when initiated early in the disease course. Early, aggressive treatment is increasingly supported by evidence showing that early disability prevention is far more effective than treating established disability.
Acute relapse treatment:
High-dose intravenous methylprednisolone (typically 1g/day for 3–5 days) reduces inflammation and shortens the duration of relapses. It does not alter long-term disability but accelerates recovery from acute attacks. Plasma exchange (plasmapheresis) is used for severe relapses unresponsive to steroids.
Disease-modifying therapy (DMT):
DMTs are categorized by efficacy tier. Moderate-efficacy therapies include injectable interferons (interferon beta-1a, beta-1b) and glatiramer acetate, and oral agents (dimethyl fumarate, teriflunomide, siponimod). High-efficacy therapies include natalizumab (IV infusion, blocks immune cell entry into the CNS), ocrelizumab (anti-CD20, depletes B-cells — the only approved therapy for both RRMS and PPMS), ofatumumab, and alemtuzumab (a highly effective but intensive immune reconstitution therapy). Treatment selection is individualized based on disease activity, patient preferences, safety monitoring requirements, and family planning.
Symptomatic management and rehabilitation:
Fatigue, spasticity, neuropathic pain, bladder dysfunction, depression, and cognitive symptoms are managed with targeted medications. Physical therapy, occupational therapy, speech therapy, and cognitive rehabilitation are essential components of comprehensive MS care. Regular aerobic exercise is strongly beneficial — it improves fatigue, mood, and cognitive function and does not worsen MS activity.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Brain MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.